Not a bad light read on valuing clinical stage biotech stocks that have and FDA approval or EMA product- hate to cross promote but ALT comes to mind here. Interesting that historically biotechs are valued at about 3 times the peak annual sales of the company's lead candidate.
Also interesting is an example of a P2 NASDAQ listed stock with a market cap of US$448m with a cancer drug in development of which only 8.1% of oncology candidates that made it phase 2 went on to earn FDA approval so low shot at success but still holding a fairly large MC- mind you peak estimated sales with full market capture are $5b so huge if it comes off but only still on an 8.1% chance and a MC of AUD approx $605. Shows the differnce between US and AUS biotech markets
https://www.google.com.au/amp/s/www...w-to-value-clinical-stage-biotech-stocks.aspx
- Forums
- ASX - By Stock
- NEU
- Bell Porter Review
Bell Porter Review, page-3
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.07 |
Change
-0.200(1.31%) |
Mkt cap ! $1.921B |
Open | High | Low | Value | Volume |
$15.38 | $15.47 | $14.99 | $1.859M | 123.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 365 | $15.05 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.07 | 950 | 26 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 390 | 15.060 |
2 | 1251 | 15.050 |
4 | 721 | 15.040 |
2 | 336 | 15.030 |
3 | 580 | 15.020 |
Price($) | Vol. | No. |
---|---|---|
15.070 | 172 | 5 |
15.080 | 345 | 9 |
15.090 | 368 | 4 |
15.100 | 704 | 6 |
15.110 | 400 | 3 |
Last trade - 11.27am 30/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |